These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35083639)

  • 1. Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.
    Jing ZY; Huo GL; Sun MF; Shen BB; Fang WJ
    Pharm Res; 2022 Feb; 39(2):399-410. PubMed ID: 35083639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of protein sub-visible particles during powder grinding of a monoclonal antibody.
    Qian C; Wang G; Wang X; Barnard J; Gao JQ; Bao W; Wang H; Li F; Ingle RG; Fang WJ
    Eur J Pharm Biopharm; 2020 Apr; 149():1-11. PubMed ID: 32006605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Sub-Visible Particle and Free Radical formation of a Freeze-Dried Monoclonal Antibody Formulation During Dropping.
    Fang WJ; Liu JW; Zheng HJ; Shen BB; Wang X; Kong Y; Jing ZY; Gao JQ
    J Pharm Sci; 2021 Apr; 110(4):1625-1634. PubMed ID: 33049261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Secondary Package on Freeze-Dried Biopharmaceutical Formulation Stability During Dropping.
    Fang WJ; Liu JW; Barnard J; Wang H; Qian YC; Xu J
    J Pharm Sci; 2021 Aug; 110(8):2916-2924. PubMed ID: 33940028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking.
    Jin MJ; Ge XZ; Huang Q; Liu JW; Ingle RG; Gao D; Fang WJ
    Pharm Res; 2024 Feb; 41(2):321-334. PubMed ID: 38291165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Freeze-Dried Biopharmaceutical Formulations are Surprisingly Less Stable than Liquid Formulations during Dropping.
    Fang WJ; Pang MJ; Liu JW; Wang X; Wang H; Sun MF
    Pharm Res; 2022 Apr; 39(4):795-803. PubMed ID: 35314998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of protein sub-visible particles during vacuum degassing of etanercept solutions.
    Wang H; Zheng HJ; Wang Z; Bai H; Carpenter JF; Chen S; Fang WJ
    Int J Biol Macromol; 2014 May; 66():151-7. PubMed ID: 24513220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freeze-Dried Monoclonal Antibody Formulations are Unexpectedly More Prone to Degradation Than Liquid Formulations Under Shaking Stress.
    Fang WJ; Ingle RG; Liu JW; Ge XZ; Wang H
    J Pharm Sci; 2022 Jul; 111(7):2134-2138. PubMed ID: 35257695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agitation-induced aggregation and subvisible particulate formation in model proteins.
    Jayaraman M; Buck PM; Ignatius AA; King KR; Wang W
    Eur J Pharm Biopharm; 2014 Jul; 87(2):299-309. PubMed ID: 24462794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary Packages cannot Protect Liquid Biopharmaceutical Formulations from Dropping-Induced Degradation.
    Fang WJ; Liu JW; Gao H; Qian YC; Gao JQ; Wang H
    Pharm Res; 2021 Aug; 38(8):1397-1404. PubMed ID: 34282500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
    Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
    Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.
    Telikepalli SN; Kumru OS; Kalonia C; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2014 Mar; 103(3):796-809. PubMed ID: 24452866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-destructive Analysis of Subvisible Particles with Mie-scattering-based Light Sheet Technology: System Development.
    Liang M; Goss M; Cao S; Yang C
    J Pharm Sci; 2024 Jul; ():. PubMed ID: 39032825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.